Sign In

Search |

Add/Edit My Facility

Functional Genomics Core Facility

Subscribe to this Core


Facility Address

Sanford Burnham Prebys Medical Discovery Institute

10901 N. Torrey Pines Road

La Jolla, CA 92037

United States

https://sbpdiscovery.org/research/shared-resources/functional-genomics/

Google Maps Location

cite this facility

Primary Contact:

Chunteng Huang

Additional Citation Identifiers

1S10OD036254-012P30CA030199-29

Facility Details

The SBP Functional Genomics Core Facility provides the infrastructure for cell-based gain-of-function (ORF, CRISPRa and CRISPRon) and loss-of-functioning (siRN, miRNA, shRNA, CRSIPRko, CRISPRi and CRISPRoff), libraries screening services, starting with assay development and carrying all the way through verification of identified targets. The large scale screens is accomplished via ready-to-use genome-wide or pathway-specific library platforms with choice of arrayed or pooled libraries. The FG core facility is equipped to perform custom CRISPR gene activation, knock-down, knock-out and editing services. We also adopt CRISPR nucleotide base editing technology and offer custom built CRISPR domain libraries. This approach can reveal the specific domain of a target protein interacting with another molecule, such as protein, IncRNA or drug in a native cell cellular environment.

Funding Info

NIH - 04/06/2024 - Beckman Coulter Biomek i7 Hybrid automated workstation

is_active:

No

budget_end:

03/31/2025

date_added:

04/06/2024

agency_code:

NIH

fiscal_year:

2024

project_num:

1S10OD036254-01

award_amount:

$594,187.00

budget_start:

04/01/2024

org_name:

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

org_state:

CA

org_country:

UNITED STATES

org_zipcode:

920371005

primary_duns:

020520466

abstract_text:

PROJECT SUMMARY Sanford Burnham Prebys Medical Discovery Institute (SBP) has 40 research labs specializing in cancer, children’s health, stem cells, degenerative diseases of aging, as well as infectious and other diseases. Many recent advances in medical research and healthcare rely on the discovery of novel therapeutic targets. Recently, advances in functional genomic technologies have provided an unprecedented opportunity to understand fundamental mechanisms underlying diseases initiation, progression, and relapse. Thus, these technologies hold great promise in the identification of novel targets and innovative treatments. In order to remain cutting-edge, the SBP Functional Genomics Core Facility seeks funding to acquire the Beckman Coulter Biomek i7 Hybrid automated workstation. This fully automated system, with 8 independent pipettes and interchangeable 96 and 384-multichannel liquid handling platforms, will replace our existing outdated, underperforming Hamilton Microlab STAR (2005 model year, 96-well platform) and Agilent Bravo (2010 model year, 384-well platform) equipment. Even after expensive software and hardware upgrades, both the Hamilton STAR and Agilent Bravo models will still fall short of automating the desired library preparation and screening workflows demanded by the NIH-funded projects that are currently being supported by our core facility. A key part of this enhancement is the production and screening of large-scale arrayed CRISPR libraries, which enables a wide variety of new scientific approaches not possible with pooled or small-scale arrayed CRISPR library analysis. In contrast to the Hamilton STAR and Agilent Bravo, the new Biomek i7 enables streamlined automation of multiple continuous pipelines and mitigates capacity limitations. Designated pipelines include high- throughput production of bacteria, viral vector plasmids, recombinant viruses, and mammalian cell cultures, as well as cell-based phenotypic screening and assay processing, which can be accomplished on a 96/384-well platform. This application is supported by eight major SBP users with active NIH-funded projects. As stated in the application, the projects of all eight major users - together accounting for 77% of the Biomek i7’s available use time (AUT) - will greatly benefit from the Biomek i7 automation to advance their proposed studies in diverse human disease research topics including cancer, aging, muscular dystrophy, Alzheimer’s disease and related dementia, and COVID-19.

project_title:

Beckman Coulter Biomek i7 Hybrid automated workstation

contact_pi_name:

HUANG, CHUN-TENG

total_cost:

$594,187.00

NIH - 09/20/2025 - Administrative Supplement to Cancer Center Support Grant (CCSG)

is_active:

No

budget_end:

08/31/2026

date_added:

09/20/2025

agency_code:

NIH

fiscal_year:

2025

project_num:

3P30CA030199-44S1

award_amount:

$194,998.00

budget_start:

09/01/2025

org_name:

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE

org_state:

CA

org_country:

UNITED STATES

org_zipcode:

920371005

primary_duns:

020520466

abstract_text:

Project Summary Early-onset breast cancer (EOBC), diagnosed in adults aged 18-49, exhibits alarming incidence increases of 1.4% annually in the U.S. compared to 0.7% in older cohorts. Among Asian American/Pacific Islander women, incidence has risen by 2.7% annually, with particularly aggressive biology characterized by higher rates of triple- negative and HER2-positive subtypes, and 10-15% lower 5-year survival rates. Despite rising incidence (1.4% annually) and 10-15% lower survival rates, a critical knowledge gap remains: why healthy young adults develop aggressive cancers decades earlier than expected. We hypothesize early-onset breast cancer arises from a distinct molecular-physical structure axis where specific lifestyle factors drive unique physical tissue changes in young women's normal breast tissue, creating cancer-prone microenvironments that bypass typical age-related cancer development pathways. Our lab's developed computational pathology methods (ecPath, TLPath) enable quantitative measurement of tissue architecture from standard H&E images. We will analyze 263 EOBC tumor biopsies and 113 normal adjacent tumor (NAT) samples (44 from EOBC cases) from The Cancer Genome Atlas (TCGA), identifying adjacent normal tissue architecture unique to EOBC transformation, connecting findings to corresponding features in Genotype-Tissue Expression Project (GTEx, 514 normal breast samples) to identify lifestyle and clinical factors accelerating cancer-prone tissue patterns, and mapping underlying molecular drivers. This research will establish the first comprehensive molecular-lifestyle-physical feature axis unique to EOBC, revealing how lifestyle factors accelerate cancer-prone tissue changes in young women and providing novel preventive intervention targets.

project_title:

Administrative Supplement to Cancer Center Support Grant (CCSG)

contact_pi_name:

BOUTROS, PAUL CHRISTOPHER

total_cost:

$194,998.00

Facility Policies

Services are offerred outside of

Consulting is offerred outside of Sanford Burnham Prebys Medical Discovery Institute

Last Updated: 10/02/2026